Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14539201 | 0.83 | TSHR (0.40) | TSHRTP53TDP1PPARDGAA | |
| SCHEMBL575511 | 0.79 | TSHR (0.46) | TSHRTP53TDP1TRPM8PPARD | |
| SCHEMBL9633264 | 0.79 | TSHR (0.55) | TSHRTP53TDP1TRPM8PPARD | |
| SCHEMBL13541606 | 0.79 | ALDH1A1 (0.35) | TRPM8GAAPOLB | |
| SCHEMBL16975426 | 0.78 | TSHR (0.40) | TSHRTP53TDP1PPARDPOLB | |
| SCHEMBL7782627 | 0.77 | CYP3A4 (0.54) | TSHRTRPM8 | |
| SCHEMBL7033791 | 0.75 | LPAR3 (0.50) | TRPM8 | |
| SCHEMBL18309148 | 0.75 | — | — | |
| SCHEMBL575282 | 0.75 | — | — | |
| SCHEMBL1107759 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382928-A1 | EUROPIUM(III) COMPLEXES AS PH SENSORS | CISBIO BIOASSAYS (FR) | 2023-11-30 | — | — | US | disclosed |
| US-20130029939-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, MPO, GCK | TSHR 787/4885TP53 4367/4885TDP1 4464/4885 |
| US-20230382928-A1 | EUROPIUM(III) COMPLEXES AS PH SENSORS | NCS1, GALR3, TAS1R3 | TSHR 330/4885TP53 2361/4885TDP1 919/4885 |
| US-20130029939-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, HK1 | TSHR 1075/4885TP53 3885/4885TDP1 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.